HealthCare Global Enterprises Limited

NSEI:HCG Stock Report

Market Cap: ₹99.5b

HealthCare Global Enterprises Future Growth

Future criteria checks 4/6

HealthCare Global Enterprises is forecast to grow earnings and revenue by 59.2% and 13.4% per annum respectively. EPS is expected to grow by 59.1% per annum. Return on equity is forecast to be 17.7% in 3 years.

Key information

59.2%

Earnings growth rate

59.15%

EPS growth rate

Healthcare earnings growth25.3%
Revenue growth rate13.4%
Future return on equity17.70%
Analyst coverage

Good

Last updated09 Jul 2026

Recent future growth updates

Recent updates

Narrative Update • Jun 22

HCG: New Cancer Hospital Expansion Will Support A Stronger Outlook

Analysts have lifted their price target on HealthCare Global Enterprises from ₹685 to ₹724, citing refreshed assumptions for revenue growth, profit margins and future P/E multiples, alongside a slightly adjusted discount rate. What's in the News HealthCare Global Enterprises plans a Special and Extraordinary Shareholders Meeting on July 8, 2026, via postal ballot in India, to seek shareholder approvals on key matters.
Narrative Update • Jun 07

HCG: Equity Raise And AOI Bid Will Drive Future Upside

Analysts now place HealthCare Global Enterprises' price target at about ₹896, down roughly ₹11 from the prior estimate of about ₹907, citing updated assumptions for revenue growth, profit margins, and future P/E multiples. What's in the News HealthCare Global Enterprises has completed a follow on equity offering of equity shares, raising ₹4.246818b through the issue of 8,294,566 common shares at ₹512 per share under a Regulation S rights offering structure.
Narrative Update • May 24

HCG: Oncology Expansion Via AOI Bid Will Support Future Upside

Analysts have nudged their fair value estimate for HealthCare Global Enterprises slightly higher from ₹900 to about ₹907, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E. What's in the News Siemens Healthineers AG is reported to be planning an exit from its India based American Oncology Institute in a potential transaction valued at around ₹15,000m to ₹20,000m, with HealthCare Global Enterprises among the bidders being considered, alongside private equity funds, as part of a wider portfolio review at Siemens Healthineers (Key Developments).
Narrative Update • Apr 29

HCG: Rights Issue And Vizag Stake Increase Will Support Future Upside

Analysts have kept their price target for HealthCare Global Enterprises steady at ₹900, indicating only slight updates to revenue growth, profit margin, and future P/E assumptions in their models. What's in the News Board meeting on Mar 30, 2026 to review an investment of up to ₹980m in HCG NCHRI LLP, a wholly owned subsidiary, and a proposed investment of up to ₹1,556.6m to acquire an additional 34% stake in Vizag Hospital from existing shareholders (company filing).
Narrative Update • Apr 15

HCG: Rights Issue And Hospital Stake Increases Will Drive Future Upside

Analysts have kept the price target for HealthCare Global Enterprises steady at ₹900. This reflects only fine tuning to revenue growth, profit margin and future P/E assumptions rather than a broad change in outlook.
Narrative Update • Apr 01

HCG: Rights Issue And Hospital Investments Will Support Future Upside

Analysts have kept the price target for HealthCare Global Enterprises steady at ₹900, citing slightly higher revenue growth and profit margin assumptions along with a somewhat lower future P/E multiple in their updated model. What's in the News Board meeting scheduled on Mar 30, 2026, to consider investment of up to ₹980 million in HCG NCHRI LLP, a wholly owned subsidiary, and up to ₹1,556.6 million for acquiring an additional 34% stake in Vizag Hospital from existing shareholders (company filing).
Narrative Update • Mar 18

HCG: Rights Issue And Margin Outlook Will Support Future Upside

Analysts have kept the fair value estimate for HealthCare Global Enterprises steady at ₹900, citing updated assumptions for revenue growth at 16.88%, profit margin at 11.90% and a slightly lower future P/E of 36.99x compared with prior inputs. What's in the News HealthCare Global Enterprises has filed a follow on equity offering of ₹4.25b through a rights issue of common equity shares under Regulation S.
Narrative Update • Mar 04

HCG: Rights Issue Plans Will Support Fair Outlook And Governance Gains

Analysts have revised their price target on HealthCare Global Enterprises from ₹787.71 to ₹761.14, citing updated assumptions around the discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News HealthCare Global Enterprises has filed a follow-on equity offering of ₹4.25b in equity shares, structured as a Regulation S rights offering to existing shareholders (Key Developments).
Narrative Update • Feb 17

HCG: Rights Issue Plan And Margin Outlook Will Support Future Upside

Analysts have lifted their price target on HealthCare Global Enterprises from ₹857.76 to ₹900.00. They cite updated assumptions that reflect a slightly different revenue growth outlook, higher profit margin expectations, a revised discount rate, and a lower future P/E multiple.
Narrative Update • Feb 03

HCG: Governance Reset And Kenya Expansion Will Support A Stronger Outlook

Analysts have maintained their fair value estimate for HealthCare Global Enterprises at ₹685.00. They have made slight adjustments to assumptions on revenue growth, profit margins and future P/E, which refine rather than overhaul their price expectations.
Narrative Update • Jan 20

HCG: Governance Changes And Kenya Expansion Will Shape A Balanced Forward Outlook

Analysts have maintained the fair value estimate for HealthCare Global Enterprises at ₹685.0. The latest narrative reflects updated assumptions that include slightly higher revenue growth, a modestly stronger profit margin, and a lower future P/E multiple. What's in the News Board meeting on November 12, 2025, to review unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2025, and to consider an investment of up to 10% in Cancer Care Kenya Limited along with a Standby Letter of Credit guarantee for its business expansion (company filing).
Narrative Update • Jan 06

HCG: Future P/E Repricing Will Support Fair Outlook And Governance Gains

Analysts have nudged their fair value estimate for HealthCare Global Enterprises higher from ₹773.71 to ₹787.71, reflecting updated assumptions around revenue growth, profit margin and future P/E expectations. What's in the News Board meeting on November 12, 2025 to review unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2025, and to consider an investment of up to 10% of the shares of Cancer Care Kenya Limited along with a Standby Letter of Credit guarantee for its expansion credit facilities (Key Developments).
Narrative Update • Dec 19

HCG: Upcoming Governance Moves And Kenya Expansion Will Shape Balanced Outlook

Analysts have raised their average price target on HealthCare Global Enterprises to ₹685 from ₹590, citing a higher justified valuation multiple that more than offsets slightly softer long term growth and margin assumptions. What's in the News Board meeting scheduled on November 12, 2025, to review unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2025, signaling upcoming visibility on the company’s earnings trajectory (Key Developments).
Narrative Update • Dec 05

HCG: Fair Outlook Will Reflect Margin Gains And Governance Developments

Analysts have raised their price target on HealthCare Global Enterprises by approximately ₹81 to reflect slightly faster expected revenue growth, improved profit margins, and a modestly lower future price to earnings multiple in their updated valuation model. What's in the News The board has scheduled a meeting for December 01, 2025, to formally appoint Chief Internal Auditor Vijay S Shanbhag as Internal Auditor for a 6 month term under Section 138 of the Companies Act, 2013 (board filing).
User avatar
New Narrative • Jan 24

Investments In AI And Genomics Will Improve Patient Outcomes

Digital initiatives and strategic acquisitions are key to revenue growth, focusing on increasing digital channel revenue and expanding patient capacity.
Analysis Article • Dec 22

Pinning Down HealthCare Global Enterprises Limited's (NSE:HCG) P/S Is Difficult Right Now

There wouldn't be many who think HealthCare Global Enterprises Limited's ( NSE:HCG ) price-to-sales (or "P/S") ratio of...
Analysis Article • Nov 13

HealthCare Global Enterprises Limited Just Missed Earnings - But Analysts Have Updated Their Models

Last week saw the newest second-quarter earnings release from HealthCare Global Enterprises Limited ( NSE:HCG ), an...
Analysis Article • Sep 19

We Take A Look At Why HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation Is Well Earned

Key Insights HealthCare Global Enterprises' Annual General Meeting to take place on 25th of September Total pay for CEO...
Analysis Article • Feb 11

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

HealthCare Global Enterprises Limited ( NSE:HCG ) missed earnings with its latest third-quarter results, disappointing...
Analysis Article • Sep 14

We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation

Key Insights HealthCare Global Enterprises' Annual General Meeting to take place on 20th of September CEO Raj Gore's...
Analysis Article • Sep 05

A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)

Key Insights Using the 2 Stage Free Cash Flow to Equity, HealthCare Global Enterprises fair value estimate is ₹377...
Analysis Article • May 17

HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price

It's not a stretch to say that HealthCare Global Enterprises Limited's ( NSE:HCG ) price-to-sales (or "P/S") ratio of...

Earnings and Revenue Growth Forecasts

NSEI:HCG - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202938,8903,4203,3277,6243
3/31/202833,3542,1182,8846,12710
3/31/202729,1061,2701,8085,12110
3/31/202625,4541385503,471N/A
12/31/202524,782190N/AN/AN/A
9/30/202524,0373541,4873,835N/A
6/30/202523,104371N/AN/AN/A
3/31/202522,2294441,0823,171N/A
12/31/202421,323583N/AN/AN/A
9/30/202420,4365709233,468N/A
6/30/202419,770526N/AN/AN/A
3/31/202419,1214829892,846N/A
12/31/202318,592353N/AN/AN/A
9/30/202318,1403719222,197N/A
6/30/202317,471309N/AN/AN/A
3/31/202316,9442931,1842,516N/A
12/31/202216,174270N/AN/AN/A
9/30/202215,507-2641,1562,364N/A
6/30/202214,827694N/AN/AN/A
3/31/202213,9785371,4892,201N/A
12/31/202113,312-544N/AN/AN/A
9/30/202112,472-3791,0891,510N/A
6/30/202111,431-1,633N/AN/AN/A
3/31/202110,134-1,9358511,205N/A
12/31/20209,858-1,349N/AN/AN/A
9/30/20209,897-1,2847511,271N/A
6/30/202010,202-1,284N/AN/AN/A
3/31/202010,956-1,0672231,301N/A
12/31/201910,832-718N/AN/AN/A
9/30/201910,541-552N/AN/AN/A
6/30/201910,210-394N/AN/AN/A
3/31/20199,787-248N/A985N/A
12/31/20189,430-135N/AN/AN/A
9/30/20189,004-41N/AN/AN/A
6/30/20188,662124N/AN/AN/A
3/31/20188,307205N/A978N/A
12/31/20177,909257N/AN/AN/A
9/30/20177,608278N/AN/AN/A
6/30/20177,237219N/AN/AN/A
3/31/20177,001230N/A913N/A
12/31/20166,705208N/AN/AN/A
9/30/20166,392133N/AN/AN/A
6/30/20166,08167N/AN/AN/A
3/31/20165,842-178N/A732N/A
12/31/20155,611-33N/AN/AN/A
9/30/20155,4949N/A763N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HCG's forecast earnings growth (59.2% per year) is above the savings rate (6.9%).

Earnings vs Market: HCG's earnings (59.2% per year) are forecast to grow faster than the Indian market (16.3% per year).

High Growth Earnings: HCG's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HCG's revenue (13.4% per year) is forecast to grow faster than the Indian market (11.1% per year).

High Growth Revenue: HCG's revenue (13.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HCG's Return on Equity is forecast to be low in 3 years time (17.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/13 11:26
End of Day Share Price 2026/07/13 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HealthCare Global Enterprises Limited is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Ashwin MehtaAmbit Capital
Gaurav TinaniAmbit Capital